Clinical Trials Using Everolimus

Clinical trials are research studies that involve people. The clinical trials on this list are studying Everolimus. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-29 of 29

  • A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    This is a Phase Ib / II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The current cohort (Cohort 1) will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4 / 6 inhibitor (CDK4 / 6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
    Location: Location information is not yet available.

  • Implantable Microdevice for the Evaluation of Drug Response in Patients with Primary Brain Tumors

    This early phase I trial studies the feasibility and safety of an implantable microdevice for the evaluation of drug response in patients with primary brain tumors. Brain tumors are known to be very different from each other and respond differently to different drugs. It would be very helpful to find out what drugs have the best chance of working in each specific tumor. This research study involves drugs that are released by a small device, as small as the tip of a needle, that is inserted by a neurosurgeon into the tumor at the time of surgery and is then removed by the end of the surgery. The goal of this research study is to prove that these small devices can be used to find out which drugs have better effects on treating tumors.
    Location: 2 locations

  • Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Metastatic or Recurrent Sarcoma

    This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.
    Location: M D Anderson Cancer Center, Houston, Texas